With more than 300 patients in the trial, dubbed FOREMOST, 33.9% of those assigned to apremilast achieved minimal disease ...

The "Psoriatic Arthritis - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.A notable advancement has been made within the Psoriatic Arthritis (PsA) therapeutic area, ...

Tremfya is a prescription drug used for psoriasis and psoriatic arthritis. Find out about possible interactions with alcohol, ...

The Food and Drug Administration (FDA) has expanded the approval of Bimzelx (bimekizumab-bkzx) to include 3 new indications.

UCB (UCBJY) (UCBJF) said it has received FDA approval for its drug Bimzelx for the treatment of active psoriatic arthritis, ...

USA: The results of the FOREMOST trial indicate that apremilast is effective for patients with early psoriatic arthritis (PsA ...

The US Food and Drug Administration has approved bimekizumab -bkzx (Bimzelx; UCB) for adult patients with active psoriatic ...

Bimekizumab-bkzx (Bimzelx) is now FDA approved for 4 chronic immune-mediated inflammatory diseases: psoriatic arthritis, nonradiographic axial spondyloarthritis (axSpA), ankylosing spondylitis, and ...

One in four participants in a European wide study aimed at detecting early signs of psoriasis showed signs of possible ...

SAN FRANCISCO, CA, UNITED STATES, September 23, 2024 /EINPresswire / -- Each year, the National Psoriasis Foundation (NPF) invites the community of ...

The FDA cleared Bimzelx to treat adults with active psoriatic arthritis (PsA), active non-radiographic axial ...

No new safety concerns and consistent safety profiles were observed for long-term risankizumab use in patients with psoriasis and PsA.